Search results
Results From The WOW.Com Content Network
Type 3 diabetes is a proposed pathological linkage between Alzheimer's disease and certain features of type 1 and type 2 diabetes. [1] Specifically, the term refers to a set of common biochemical and metabolic features seen in the brain in Alzheimer's disease, and in other tissues in diabetes; [1] [2] it may thus be considered a "brain-specific type of diabetes."
Multi-infarct dementia results from a series of small strokes affecting several brain regions. Stroke-related dementia involving successive small strokes causes a more gradual decline in cognition. [4] Dementia may occur when neurodegenerative and cerebrovascular pathologies are mixed, as in susceptible elderly people (75 years and older).
The lysosomal storage diseases are generally classified by the nature of the primary stored material involved, and can be broadly broken into the following: (ICD-10 codes are provided where available) [citation needed] (E75) Lipid storage disorders. Gangliosidoses (including Tay–Sachs disease (E75.0-E75.1) - they are a subtype of sphingolipidoses
SGLT2 inhibitors lowered dementia, Parkinson’s risk by 22%. For this study, the researchers accessed data from 358,862 participants with type 2 diabetes and followed them for an average of 9.6 ...
Most neurons have the ability to use other fuels besides glucose (e.g. lactic acid, ketones).Knowledge of the "switchover" process is incomplete. [further explanation needed] The most severe neuroglycopenic symptoms occur with hypoglycemia caused by excess insulin because insulin reduces the availability of other fuels by suppressing ketogenesis and gluconeogenesis.
Dementia with Lewy bodies (DLB) is a type of dementia, a group of diseases involving progressive neurodegeneration of the central nervous system. [11] It is one of the two Lewy body dementias, along with Parkinson's disease dementia. [12] Dementia with Lewy bodies can be classified in other ways.
The analysis showed that over a follow-up period of an average of 2.06 years for people on SGLT2 inhibitors, and 3.70 years for people on different antidiabetes drugs, there was a reduction in the ...
For premium support please call: 800-290-4726 more ways to reach us